Brandt, Roemer B.
Doesborg, Patty G. G.
Meilof, Roy
de Coo, Ilse F.
Bartels, Eveline
Ferrari, Michel D.
Fronczek, Rolf
Article History
Received: 23 February 2021
Accepted: 8 June 2021
First Online: 22 June 2021
Declarations
:
: R.B<b>.</b> Brandt has received support for conference visits from Allergan. I.F. de Coo has received support for conference visits from Electrocore. M.D. Ferrari reports consultancy fees from Medtronic, Amgen, Lilly and Electrocore and independent support from the Dutch Heart Foundation, NWO, ZonMW, Fonds Nuts Ohra, NIH and the European Community. R. Fronczek has carried out advisory work for Lilly, TEVA and Allergan, received lecture fees from Novartis, reports grants from Dutch Brain Foundation and Innovatiefonds Zorgverzekeraars and received support for conference visits from Allergan. P.G.G. Doesborg, R. Meilof and E. Bartels report no disclosures.
: The study (ID:G17.028) was approved by the local ethics committee (<i>Commissie Medische Ethiek LUMC Leiden</i>).
: All patients that visit the headache clinic provide written informed consent for the use of their data in future studies. For this specific study, no written informed consent was obtained, as per approval by the local ethics committee.
: • GON-injection can be a viable treatment option in medically intractable chronic cluster headache.• Repeated GON-injections show similar effect to a first GON-injection in (medically intractable) chronic cluster headache.